Wayne Camarco
SPI Pharma, UK
Scientific Tracks Abstracts: J Med Chem
Regulators are requiring formulators to take the needs of the patient into account as they create new dosage forms. This means that the organoleptic of the dose form must be taken into account from the beginning of any project, in addition to standard variables like stability, efficacy, content uniformity, robustness, and manufacturability. The number of patient- centric dose forms entering the market has significantly increased in solid dose form design as a means of meeting these criteria. Orally disintegrating tablets (ODTs), chewable tablets, granules, resuspendable tablets or granules and orally dispersible powders are all examples of dose forms that help to improve patient adherence, particularly in patient groups – such as paediatrics and elderly patients – where this can be particularly challenging. Orally disintegrating or chewable dosages with a pleasant flavor and texture are examples of dosages that can be used to increase patient adherence. Excipients that help formulators achieve these goals haven't been introduced much despite the changing demands of both patients and authorities. Excipient companies must invest time and money in developing new excipients or improving the functionality of current ones. The rewards frequently fall short of the endeavors made. In order to solve this dilemma, excipient providers must reason through what the ideal "universal excipient" might entail.
Wayne Camarco joined SPI Pharma in 2019 as Global Head of Technical Development. He has broad-based excipient and API experience in the areas of formulation development and technical service. He has worked in a variety of technical, sales and business development roles at ACG Capsules in the US, Juniper Pharma (Catalent, UK), Ashland Specialty Ingredients (US) and Rhodia (US and France).
Medicinal Chemistry received 6627 citations as per Google Scholar report
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 